ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) Announces Positive Pre-clinical Data on Darinaparsin in Leukemia Publication
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs, recently announced the publication of results from a pre-clinical study of darinaparsin (ZIO-101) in the July 17, 2008 online advance publication issue of Leukemia, a Nature publication. Darinaparsin is a proprietary small molecule organic arsenic licensed from The University of Texas M. D. Anderson Cancer Center and Texas A&M University that induces cell cycle arrest and cell death by targeting several cellular pathways essential for cell survival. The study showed that darinaparsin…